Claims for Patent: 8,048,872

Summary for Patent: 8,048,872

Title:	Treatment of hyperproliferative diseases with vinca alkaloid N-oxide and analogs
Abstract:	The present invention relates to vinca alkaloid and analog N-oxides having activity for treating hyperproliferative disorders. Further, the invention relates to pharmaceutical compositions and methods of using vinca alkaloid and analog N-oxides, alone or in combination with one or more other active agents or treatments, to treat hyperproliferative disorders.
Inventor(s):	Curd; John G. (Hillsborough, CA), Keana; John F. W. (Eugene, OR), Lalani; Alshad S. (Tarrytown, NY), Westberg; Paul B. (San Mateo, CA), Goodwin; Bradford (San Mateo, CA), Henner; W. David (Tucson, AZ)
Assignee:	Stat of Oregon Acting by and Through The Oregon State Board of Higher Education on Behalf of the University of Oregon (Eugene, OR) N/A (N/A)
Application Number:	12/111,672
Patent Claims:	1. A compound selected from the group consisting of desacetyl vinflunine N-oxide, desacetyl vinorelbine N-oxide, and vinflunine N-oxide, or a pharmaceutically acceptable salt thereof. 2. The compound of claim 1, which is vinflunine N-oxide, or a pharmaceutically acceptable salt thereof. 3. The compound of claim 2, wherein said pharmaceutically acceptable salt is the dihydrochloride salt. 4. A pharmaceutical composition comprising a compound selected from the group consisting of vinblastine N-oxide, desacetyl vinblastine N-oxide, vinorelbine N-oxide, vincristine N-oxide, desacetyl vinflunine N-oxide, desacetyl vinorelbine N-oxide, vindesine N-oxide and vinflunine N-oxide or a pharmaceutically acceptable salt thereof. 5. The pharmaceutical composition of claim 4, further comprising a topoisomerase 1 inhibitor. 6. The pharmaceutical composition of claim 5, wherein said topoisomerase 1 inhibitor is selected from the group consisting of topotecan, irinotecan, 9-aminocamptothecin, 10-aminocamptothecin, 10,11-methylenedioxycamptothecin and SN-38. 7. The pharmaceutical composition of claim 4, wherein said compound is vincristine N-oxide, or a pharmaceutically acceptable salt thereof. 8. The pharmaceutical composition of claim 7, wherein said pharmaceutically acceptable salt is the dihydrochloride salt. 9. The pharmaceutical composition of claim 4, wherein said compound is vinblastine N-oxide, or a pharmaceutically acceptable salt thereof. 10. The pharmaceutical composition of claim 9, wherein said pharmaceutically acceptable salt is the dihydrochloride salt. 11. The pharmaceutical composition of claim 6, wherein the topoisomerase 1 inhibitor is irinotecan and the compound is vinblastine N-oxide or vincristine N-oxide. 12. The pharmaceutical composition of claim 4, further comprising one or more active agents independently selected from the group consisting of chemotherapeutic agents, anti-angiogenesis agents, vascular targeting agents, HIF1 inhibitors, Hsp90 inhibitors, a tyrosine kinase inhibitor, a serine/threonine kinase inhibitor, a proteasome inhibitor, an HDAC inibitor, a caspase inducer, a CDK inhibitor, and a proapoptotic molecule. 13. The pharmaceutical composition of claim 12, wherein said chemotherapeutic agent is selected from the group consisting of abarelix, aldesleukin, alemtuzumab, alitretinoin, allopurinol, altretamine, amifostine, anastrozole, arsenic trioxide, asparaginase, BCG live, bevaceizumab, bexarotene, bleomycin, bortezomib, busulfan, calusterone, camptothecin, capecitabine, carboplatin, carmustine, celecoxib, cetuximab, chlorambucil, cinacalcet, cisplatin, cladribine, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, darbepoetin alfa, daunorubicin, denileukin diftitox, dexrazoxane, docetaxel, doxorubicin, dromostanolone, Elliott's B solution, epirubicin, epoetin alfa, estramustine, etoposide, exemestane, filgrastim, floxuridine, fludarabine, fluorouracil, fulvestrant, gemcitabine, gemtuzumab ozogamicin, gefitinib, goserelin, hydroxyurea, ibritumomab tiuxetan, idarubicin, ifosfamide, imatinib, interferon alfa-2a, interferon alfa-2b, irinotecan, letrozole, leucovorin, levamisole, lomustine, meclorethamine, megestrol, melphalan, mercaptopurine, mesna, methotrexate, methoxsalen, methylprednisolone, mitomycin C, mitotane, mitoxantrone, nandrolone, nofetumomab, oblimersen, oprelvekin, oxaliplatin, paclitaxel, pamidronate, pegademase, pegaspargase, pegfilgrastim, pemetrexed, pentostatin, pipobroman, plicamycin, polifeprosan, porfimer, procarbazine, quinacrine, rasburicase, rituximab, sargramostim, streptozocin, talc, tamoxifen, tarceva, temozolomide, teniposide, testolactone, thioguanine, thiotepa, topotecan, toremifene, tositumomab, trastuzumab, tretinoin, uracil mustard, valrubicin, vinblastine, vincristine, vinorelbine, and zoledronate. 14. The pharmaceutical composition of claim 12, wherein said anti-angiogenesis agent is selected from the group consisting of bevacizumab, angiostatin, endostatin, batimastat, captopril, cartilage derived inhibitor, genistein, interleukin 12, lavendustin, medroxypregesterone acetate, recombinant human platelet factor 4, tecogalan, thrombospondin, TNP-470, anti-VEGF monoclonal antibody, soluble VEGF-receptor chimaeric protein, anti-VEGF receptor antibodies, anti-PDGF receptors, inhibitors of integrins, tyrosine kinase inhibitors, serine/threonine kinase inhibitors, antisense oligonucleotides, antisense oligodexoynucleotides, siRNAs, anti-VEGF aptamers and pigment epithelium derived factor. 15. The compound of claim 1, which is desacetyl vinflunine N-oxide, or a pharmaceutically acceptable salt thereof. 16. The compound of claim 1, which is desacetyl vinorelbine N-oxide, or a pharmaceutically acceptable salt thereof. 17. The pharmaceutical composition of claim 4, wherein said compound is desacetyl vinblastine N-oxide, or a pharmaceutically acceptable salt thereof. 18. The pharmaceutical composition of claim 4, wherein said compound is vinorelbine N-oxide, or a pharmaceutically acceptable salt thereof. 19. The pharmaceutical composition of claim 4, wherein said compound is desacetyl vinflunine N-oxide, or a pharmaceutically acceptable salt thereof. 20. The pharmaceutical composition of claim 4, wherein said compound is desacetyl vinorelbine N-oxide, or a pharmaceutically acceptable salt thereof. 21. The pharmaceutical composition of claim 4, wherein said compound is vindesine N-oxide, or a pharmaceutically acceptable salt thereof. 22. The pharmaceutical composition of claim 4, wherein said compound is vinflunine N-oxide, or a pharmaceutically acceptable salt thereof.

Details for Patent 8,048,872

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2026-02-17
Merck Teknika Llc	TICE BCG	bcg live	For Injection	102821	06/21/1989		2026-02-17
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2026-02-17
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2026-02-17
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2026-02-17